Novo Nordisk’s adjusted operating profit reached DKK 32,858 million in Q1 2026
Bagsværd, Denmark, 6 May 2026 - Financial report for the period 1…
Novo Nordisks Wegovy cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular disease
Compared with tirzepatide, Wegovy® (semaglutide 2.4 mg) showed a significant 57% greater…


